Invasive malignant thymoma

Summary

Invasive malignant thymoma (MONDO:0002592) is a disease. A subtype of thymic carcinoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	invasive malignant thymoma
Mondo ID	MONDO:0002592
DOID	DOID:3283
NCIT	C7904
UMLS	C0278846
MedGen	78892
GARD	0023180
Is cancer (heuristic)	no

Also known as: invasive malignant thymoma · malignant thymoma, invasive · thymoma malignant invasive

Disease family

This is a subtype of thymic carcinoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › immune system cancer › thymus cancer › thymic carcinoma › invasive malignant thymoma

Related subtypes (8): thymus gland adenocarcinoma, thymus squamous cell carcinoma, malignant type AB thymoma, lymphoepithelioma-like thymic carcinoma, thymus clear cell carcinoma, thymic sarcomatoid carcinoma, thymic undifferentiated carcinoma, thymic neuroendocrine carcinoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.